Compare SRRK & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | GTLB |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.9B |
| IPO Year | 2018 | 2021 |
| Metric | SRRK | GTLB |
|---|---|---|
| Price | $42.47 | $20.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 28 |
| Target Price | ★ $55.40 | $40.96 |
| AVG Volume (30 Days) | 1.3M | ★ 6.4M |
| Earning Date | 03-03-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $955,224,000.00 |
| Revenue This Year | N/A | $20.08 |
| Revenue Next Year | $449.79 | $18.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.81 |
| 52 Week Low | $22.71 | $21.98 |
| 52 Week High | $49.82 | $53.55 |
| Indicator | SRRK | GTLB |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 25.05 |
| Support Level | $41.54 | N/A |
| Resistance Level | $42.54 | $50.50 |
| Average True Range (ATR) | 2.40 | 0.91 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 38.83 | 0.00 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.